NCT06186986View on ClinicalTrials.gov

CD30 Imaging in Diffuse Large B-cell Lymphoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions

Diffuse Large B-cell-lymphoma

Interventions

DRUG

Brentuximab vedotin

5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

University Medical Center Groningen

OTHER